functions for the compression of a bivariate discrete measure Search Results


cubicle  (AutoMate Scientific Inc)
96
AutoMate Scientific Inc cubicle
Cubicle, supplied by AutoMate Scientific Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cubicle/product/AutoMate Scientific Inc
Average 96 stars, based on 1 article reviews
cubicle - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
ofa  (Glaxo Smith)
90
Glaxo Smith ofa
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Ofa, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ofa/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
ofa - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ofa  (Konan Medical USA)
90
Konan Medical USA ofa
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Ofa, supplied by Konan Medical USA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ofa/product/Konan Medical USA
Average 90 stars, based on 1 article reviews
ofa - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ofa  (Genmab Inc)
90
Genmab Inc ofa
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Ofa, supplied by Genmab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ofa/product/Genmab Inc
Average 90 stars, based on 1 article reviews
ofa - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ofa  (Emisphere)
90
Emisphere ofa
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Ofa, supplied by Emisphere, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ofa/product/Emisphere
Average 90 stars, based on 1 article reviews
ofa - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
a. ureafaciens sialidase nacalai tesque  (Nacalai)
90
Nacalai a. ureafaciens sialidase nacalai tesque
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
A. Ureafaciens Sialidase Nacalai Tesque, supplied by Nacalai, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a. ureafaciens sialidase nacalai tesque/product/Nacalai
Average 90 stars, based on 1 article reviews
a. ureafaciens sialidase nacalai tesque - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ofa-ilrp  (Rieser GmbH)
90
Rieser GmbH ofa-ilrp
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Ofa Ilrp, supplied by Rieser GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ofa-ilrp/product/Rieser GmbH
Average 90 stars, based on 1 article reviews
ofa-ilrp - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
sprague–dawley (ofa-sd) rat strain  (Dawley Inc)
90
Dawley Inc sprague–dawley (ofa-sd) rat strain
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Sprague–Dawley (Ofa Sd) Rat Strain, supplied by Dawley Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sprague–dawley (ofa-sd) rat strain/product/Dawley Inc
Average 90 stars, based on 1 article reviews
sprague–dawley (ofa-sd) rat strain - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
minigita ofa probe  (Raytest GmbH)
90
Raytest GmbH minigita ofa probe
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Minigita Ofa Probe, supplied by Raytest GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/minigita ofa probe/product/Raytest GmbH
Average 90 stars, based on 1 article reviews
minigita ofa probe - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
elysia-raytest minigita tlc reader with ofa probe and tungsten collimator  (Raytest GmbH)
90
Raytest GmbH elysia-raytest minigita tlc reader with ofa probe and tungsten collimator
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Elysia Raytest Minigita Tlc Reader With Ofa Probe And Tungsten Collimator, supplied by Raytest GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/elysia-raytest minigita tlc reader with ofa probe and tungsten collimator/product/Raytest GmbH
Average 90 stars, based on 1 article reviews
elysia-raytest minigita tlc reader with ofa probe and tungsten collimator - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
photodetector det01cfc/m  (Thorlabs)
90
Thorlabs photodetector det01cfc/m
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
Photodetector Det01cfc/M, supplied by Thorlabs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/photodetector det01cfc/m/product/Thorlabs
Average 90 stars, based on 1 article reviews
photodetector det01cfc/m - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
a. coerulea ephyrae  (Rongcheng Mashan Group Co Ltd)
90
Rongcheng Mashan Group Co Ltd a. coerulea ephyrae
CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of <t>ofatumumab</t> <t>(OFA)</t> were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.
A. Coerulea Ephyrae, supplied by Rongcheng Mashan Group Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a. coerulea ephyrae/product/Rongcheng Mashan Group Co Ltd
Average 90 stars, based on 1 article reviews
a. coerulea ephyrae - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of ofatumumab (OFA) were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Induced Resistance to Ofatumumab Mediated Cell Clearance Mechanisms, Including Complement Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia

doi: 10.4049/jimmunol.1302954

Figure Lengend Snippet: CLL cells obtained from patients before treatment (0hr), and then at 8hr and 24hr after the start of the administration of the first dose of ofatumumab (OFA) were tested for in vitro CDC using saturating doses (10 μg/ml) of rituximab (RTX), OFA, or alemtuzumab (ALM)and 10% normal human serum (NHS) as a source of complement. RTX induced low levels of CDC. Compared to OFA CDC in pre-treatment specimens (median 37% cytotoxicity, range 0 – 83) there was a significant decrease in OFA CDC at 8hr (median 0%, range 0 – 5)(p<0.0001) and 24hr (median 0%, range 0 – 32) (p<0.0001). In contrast, ALM CDC was not decreased by in vivo exposure of CLL cells to OFA.

Article Snippet: OFA standards were prepared by serial dilutions of a commercial sample of OFA (GlaxoSmithKline, Research Triangle Park, NC) into pooled normal human serum.

Techniques: In Vitro, In Vivo